维达列汀杂质71 | 16214-29-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 维达列汀杂质71
• 英文名称: trans-4-chloro-L-proline
• 英文别名: trans-4-Chlor-L-prolin；(4R)-4-Chloro-L-proline；(2S,4R)-4-chloropyrrolidine-2-carboxylic acid
• CAS: 16214-29-2
• 化学式: C₅H₈ClNO₂
• 分子量: 149.577
• InChiKey: UYZNMRJCNSDDFV-DMTCNVIQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.1
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  维达列汀杂质71 、 alkaline earth salt of/the/ methylsulfuric acid 生成 3-Hydroxy-pyridine-2-carboxylic acid [(2R,23aR)-2-chloro-18-(1,2-dimethyl-propyl)-5-isobutyl-9,13,15,19,22-pentamethyl-4,7,11,14,17,20,23-heptaoxo-12-phenyl-docosahydro-10-oxa-3a,6,13,16,19,22-hexaaza-cyclopentacyclodocosen-8-yl]-amide
  参考文献：
  名称：

  Neoviridogrisein-Cls, new analogs of viridogrisein, produced under the supplementation of 4-chloro-L-proline.

  摘要：

  DOI：

  10.1271/bbb1961.48.543

文献信息

• N-arylsulfonamide and pyrrolidinecarboxylic acid intermediates, and their use for the preparation of herbicidal 1,3-dioxo-1h-pyrrolo[1,2-c]imidazole derivatives
  申请人：DEGUSSA AG

  公开号：US20020137946A1

  公开（公告）日：2002-09-26

  This invention is directed to compounds and intermediates of Formulae (6 and 3), useful in preparing herbicidal sulfonamides of Formula (1), including all geometric and stereoisomers thereof, and agricultural salts thereof, wherein X is H, F or Cl; Y is F or Cl; R 1 is C 1 -C 3 haloalkyl, C 2 -C 4 alkoxyalkyl; C 2 -C 6 haloalkoxyalkyl or C 2 -C 6 cyanoalkyl; R 2 is H, C 1 -C 4 alkyl, C 1 -C4 haloalkyl; C 3 -C 4 alkenyl, C 3 -C 4 alkynyl, C 2 -C 4 alkoxyalkyl, C 2 -C 4 alkylcarbonyl or C 2 -C 4 alkoxycarbonyl; R 3 is H or OH; R 4 is H, F or Cl; and R 5 is F or Cl; provided that when R 3 is H then R 4 is F or Cl and when R 3 is OH then R 4 is H.

  本发明涉及公式（6和3）的化合物和中间体，其可用于制备公式（1）的除草磺胺类化合物，包括其所有几何和立体异构体，以及农业盐，其中X为H，F或Cl; Y为F或Cl; R1为C1-C3卤代烷基，C2-C4烷氧基烷基; C2-C6卤代烷氧基烷基或C2-C6氰基烷基; R2为H，C1-C4烷基，C1-C4卤代烷基; C3-C4烯基，C3-C4炔基，C2-C4烷氧基烷基，C2-C4烷基羰基或C2-C4烷氧羰基; R3为H或OH; R4为H，F或Cl; R5为F或Cl; 前提是当R3为H时，R4为F或Cl，当R3为OH时，R4为H。
• STABILIZATION OF THE COLLAGEN TRIPLE HELIX BY O-METHYLATION OF HYDROXYPROLINE RESIDUES
  申请人：Raines Ronald T.

  公开号：US20090264626A1

  公开（公告）日：2009-10-22

  This invention relates to a collagen polypeptide comprising a tripeptide motif having the formula (ProYaaGly) n , where Yaa is an O-methylated amino acid residue and “n” is the number of motif repeats. Preferred O-methylated amino acid residues at the Yaa position include (2S,4R)-4-methoxyproline. Other suitable amino acid residues at that position include O-mono or O-di-halogenated methylproline. Also, disclosed is a method of making a synthetic or a semi-synthetic collagen polypeptide molecule having increased stability relative to natural collagen. The strengthened collagen molecules are suitable for use in biomaterials for the medical field or in leather-related products prepared by the tanning industry.

  本发明涉及一种胶原蛋白多肽，其包含具有公式（ProYaaGly）n的三肽基序，其中Yaa是O-甲基化的氨基酸残基，“n”是基序重复的次数。在Yaa位置的首选O-甲基化氨基酸残基包括（2S，4R）-4-甲氧基脯氨酸。该位置上的其他适当氨基酸残基包括O-单或O-双卤代甲基脯氨酸。此外，还揭示了一种制备具有相对于天然胶原蛋白增强稳定性的合成或半合成胶原蛋白分子的方法。强化的胶原分子适用于医学领域的生物材料或由制革工业制备的皮革相关产品。
• Therapeutic compounds and methods of use thereof
  申请人：GENENTECH, INC.

  公开号：US10005724B2

  公开（公告）日：2018-06-26

  The invention provides compounds having the general Formula (I); and pharmaceutically acceptable salts thereof; wherein the variables RA, RAA, subscript n, subscript q, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, D and E have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

  本发明提供具有通式（I）的化合物；及其药学上可接受的盐；其中变量 RA、RAA、下标 n、下标 q、环 A、X2、L、下标 m、X1、R1、R2、R3、R4、R5、D 和 E 具有本文所述的含义，以及含有此类化合物的组合物和使用此类化合物及组合物的方法。
• Non-canonical insulins and their uses
  申请人：California Institute of Technology

  公开号：US10640546B2

  公开（公告）日：2020-05-05

  In some aspects, the invention relates to an insulin derivative, comprising a cyclic amino acid at position B28 or B29, wherein the cyclic amino acid is not L-proline. In some aspects, the invention relates to a method of making said insulin derivative. In some aspects, the invention relates to a pharmaceutical composition comprising said insulin derivative. In some aspects the invention relates to a method of treating a disease or condition in a subject comprising administering to the subject a composition comprising said insulin derivative.

  在某些方面，本发明涉及一种胰岛素衍生物，其包含位于 B28 或 B29 位的环状氨基酸，其中环状氨基酸不是 L-脯氨酸。在某些方面，本发明涉及一种制造所述胰岛素衍生物的方法。在某些方面，本发明涉及一种包含所述胰岛素衍生物的药物组合物。在某些方面，本发明涉及一种治疗受试者疾病或状况的方法，该方法包括向受试者施用包含所述胰岛素衍生物的组合物。
• THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Genentech, Inc.

  公开号：EP3166939B1

  公开（公告）日：2019-06-05